文献速递消化道肿瘤放疗放疗物理与技术

碳离子放疗联合风险适应剂量递增治疗胰腺癌的初步临床经验

Carbon ion therapy for pancreatic cancer with risk-adapted dose escalation: initial clinical experience.
PubMed 文献 · Radiother Oncol · 2025-10-30

BACKGROUND AND PURPOSE: This study reports the initial clinical outcomes of carbon ion radiotherapy (CIRT) using a risk-adapted dose-escalation protocol for pancreatic cancer at Taiwan's first heavy-ion therapy center.…

要点

  • 碳离子放疗风险适应剂量递增方案在胰腺癌中实现1年局部控制率94.7%。
  • 转移性疾病、新辅助化疗超过9个月及CA19-9≥120 U/mL与更差生存相关。
  • 急性毒性以1级为主,≥3级毒性很少。

核心结论

  • 碳离子放疗联合风险适应剂量递增在胰腺癌(包括解剖困难病例)中产生优异的局部控制和低毒性。

主要发现

  • 中位随访12.7个月,1年局部控制率94.7%、总生存率75.3%、无远处转移生存率44.5%、无进展生存率42.9%。
  • 非转移患者中位无进展生存期为13.6个月。
  • 转移性疾病、新辅助化疗超过9个月及CA19-9≥120 U/mL与更差的总生存、无远处转移生存和无进展生存相关。
  • CA19-9动力学(新辅助化疗期间持续下降或反弹但低于基线)与更好的生存和局部控制相关。
  • 大多数急性事件为1级毒性,≥3级毒性很少。

关键数值与推荐

  • 剂量递增方案:PET avid病灶和肿瘤-血管界面为60-66 Gy(RBE),大体肿瘤体积为55.2 Gy(RBE),亚临床区域为43.2 Gy(RBE)。
  • 所有患者接受新辅助化疗,中位持续时间4.27个月。

临床怎么用

  • 可考虑将碳离子放疗风险适应剂量递增作为局部晚期或寡转移胰腺癌的根治性放疗选择。
  • 治疗决策中可结合CA19-9动力学及新辅助化疗时长评估风险。

局限性

  • 为单中心初步临床经验,随访时间较短(中位12.7个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: This study reports the initial clinical outcomes of carbon ion radiotherapy (CIRT) using a risk-adapted dose-escalation protocol for pancreatic cancer at Taiwan's first heavy-ion therapy center. MATERIALS AND METHODS: Eighty-four patients, primarily with locally advanced or oligometastatic disease, received definitive CIRT in 12 fractions. Doses were escalated to 60-66 Gy(RBE) for PET-avid lesions and tumor-vessel interfaces, 55.2 Gy(RBE) for gross tumor volume, and 43.2 Gy(RBE) for subclinical regions. All patients underwent neoadjuvant chemotherapy (NAC) for a median of 4.27 months. Kaplan-Meier and Cox regression were used to assess outcomes and prognostic factors. RESULTS: As of March 25, 2025, with a median follow-up of 12.7 months, 1-year rates for local tumor control (LTC), overall survival (OS), distant metastasis-free survival (DMFS), and progression-free survival (PFS) were 94.7 %, 75.3 %, 44.5 %, and 42.9 %, respectively. Among non-metastatic patients, median PFS was 13.6 months. Poorer OS, DMFS, and PFS were linked to metastatic disease, prolonged NAC (>9 months), and elevated CA19-9 (≥120 U/mL). Improved survival and local control were associated with CA19-9 kinetics, specifically a prolonged decline or rebound that stayed below baseline during NAC. The majority of acute events were restricted to Grade 1 toxicities, and there were very few Grade ≥3 toxicities. CONCLUSION: In pancreatic cancer, including anatomically difficult cases, CIRT with risk-adapted dose escalation produced excellent local control and low toxicity. Results could be further enhanced by CA19-9 dynamics and the best time to start CIRT. Integration with systemic therapies should be investigated in future trials.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Lai IC, Kang YM, Wu YH, et al. Carbon ion therapy for pancreatic cancer with risk-adapted dose escalation: initial clinical experience. Radiother Oncol. 2025. PMID: 41176067. doi:10.1016/j.radonc.2025.111238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。